EVH logo

EVOLENT HEALTH INC - A

EVHNYSE
πŸ† #3130 by market capEarnings Nov 4 Β· PostUS Equity
$1,017.75β–Ό $65.14 (βˆ’6.40%)
Simulated price
πŸ””
Track EVH
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 6.4%
7dβ–² 26682.9%
14dβ–² 27112.6%
30dβ–² 22025.0%
ytdβ–² 25375.6%
1yβ–² 11524.8%
🏦Market Cap
$406M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-26.6%
Declining
πŸ“ŠGross Margin
12.9%
Thin
πŸ’΅FCF Margin
0.8%
Thin
βš–οΈP/S Ratio
0.2x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$1,004.77 – $1,033.86
52-Week Range
$2.10 – $8.98
Volume
$5.66B
Avg Volume
$5.83B
Shares Outstanding
112.5M
Next Earnings
Nov 6, 2026

Fundamentals Snapshot

Annual Revenue
$1.88B
Last Q Revenue
$653M
P/E Ratio
-0.8
P/S Ratio
0.2x
EPS (TTM)
$-4.49
Dividend Yield
0.00%
Dilution (1yr)
βˆ’0.7%

Why Investors Own EVH

  • βœ“High-growth profile β€” revenue up +0.4% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 48% gross margin and 7% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

EVH logo

EVOLENT HEALTH INC - A

EVH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.9Bβ–Ό βˆ’26.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
15.1%β–² +5.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$4Mβ–Ό βˆ’89.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$5Mβ–Ό βˆ’177.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
114.2Mβ–Ό βˆ’0.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$838Mβ–Ό βˆ’$228M YoY
StockOtter Β· stockotter.space

About EVOLENT HEALTH INC - A

Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
60/100

Analyst Price Target

β“˜
Average Target
$1,095.26
β–² +7.6% Upside
High Target$1,283.23
Low Target$1,020.71
Based on 25 analysts

Latest News & Updates